Comparing Two Weight-Loss Drugs on Bone and Body Composition in Obesity
Compares tirzepatide and liraglutide effects on bone markers and body makeup in adults with obesity.
Plain-language title generated from the registry record
Registry title: Tirzepatide vs Liraglutide in Bone
Key facts
- Where
- Athens, GreeceSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 30 and 65 years old?
Source: NCT07094568, who can take part
Where in Greece
- Laiko General HospitalAthens, GreeceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- National and Kapodistrian University of Athens
- Trial code
- NCT07094568
- Record updated
- 21 January 2026
- Original description
This prospective cohort study investigates the effects of tirzepatide versus liraglutide on bone turnover markers and body composition in adults with class 3 obesity, characterised by Body Mass Index (BMI) ≥40 kg/m². Participants will be followed for 6 months with assessments at baseline, 3 and 6. The primary outcome is the change in bone resorption marker C-terminal telopeptide of type I collagen (CTX) at 3 months. Secondary outcomes include changes in body weight, BMI, bone mineral density (BMD), and body composition. The study aims to clarify the differential impact of weight loss achieved through tirzepatide versus liraglutide on bone metabolism and body composition in adults with obesity.Read full original descriptionShow less
Comparative Investigation of Changes in Body Composition and Bone Turnover Markers in People With Obesity After Treatment With Tirzepatide Versus Liraglutide. A Prospective Cohort Study.
This prospective cohort study investigates the effects of tirzepatide versus liraglutide on bone turnover markers and body composition in adults with class 3 obesity, characterised by Body Mass Index (BMI) ≥40 kg/m². Participants will be followed for 6 months with assessments at baseline, 3 and 6. The primary outcome is the change in bone resorption marker C-terminal telopeptide of type I collagen (CTX) at 3 months. Secondary outcomes include changes in body weight, BMI, bone mineral density (BMD), and body composition. The study aims to clarify the differential impact of weight loss achieved through tirzepatide versus liraglutide on bone metabolism and body composition in adults with obesity.
Inclusion: Adults aged between 30 and 65 years; BMI ≥40 kg/m².
Exclusion: Previous bariatric or gastrointestinal surgery involving intestinal bypass; Medications which can affect bone markers: bone-anabolic agents, antiresorptive agents, antiandrogenic agents, vitamin K antagonists, antipsychotic agents, contraceptives, glucocorticoids (oral), methotrexate, thiazides, aromatase inhibitors etc); Type 2 Diabetes Mellitus (T2DM) and type 1 Diabetes Mellitus (T1DM); Chronic kidney disease; Liver failure; Heart failure; Malignancy coexistence; Rare Metabolic Bone Diseases (e.g., Paget's disease of bone, fibrous dysplasia, osteopetrosis); Uncontrolled hypo/hyperthyroidism; Uncontrolled hypo/hyperparathyroidism; Pregnancy and lactation; Recent fracture (within 2 years); Inflammatory arthritis; Hemolytic anemia.